Nelkarmi Wins Accelerated FDA Approval for ALK-Positive Lung Cancer That Progressed After Alectinib or Two Earlier Drugs
6 outletsin 1 language and 2 countriesFirst reported , latest
Every report 6 reports
- FDA Grants Accelerated Approval to Nelkarmi for Pretreated ALK+ NSCLC
Cancer Therapy Advisor
Add to CRMAlso published by empr.com